Input 2021.02.17 11:46
Celltrion (068270)Has started accepting supply applications for each medical institution on the 16th, and announced that it will begin supplying in earnest on the 17th, starting with the medical institution that submitted the supply application on the first day of receipt. Celltrion Pharmaceutical, a subsidiary that has the right to supply Celltrion antibody drugs in Korea, will supply Rekirona in Korea.
The treatment is provided free of charge to patients and can be supplied by filling out a supply request form directly from 156 designated Corona 19 treatment medical institutions nationwide and applying to Celltrion Pharmaceutical. Celltrion Pharmaceutical will immediately deliver the medicine to the relevant medical institution after confirming the requested supply request. In addition, after dispensing drugs, the drug dispensing status is written and submitted to the Korea Centers for Disease Control and Prevention, and the Agency plans to manage the inventory management and medication status of the treatment.
Treatment targets are confirmed patients with COVID-19 based on the scope approved by the Ministry of Food and Drug Safety, within 7 days from the date of onset of symptoms, 60 years of age or older among patients who do not require oxygen therapy, cardiovascular disease, chronic respiratory disease, diabetes, hypertension Patients with underlying diseases of the back or patients with pneumonia.
Details regarding the supply of therapeutic agents will be announced separately to medical institutions through each city/province.
Celltrion has completed the production of Rekirona for 100,000 people for the purpose of treating domestic patients, and plans to produce 1.5 to 3 million people per year depending on demand.